Li Zhang

机构：Sichuan University, West China Hospital of Sichuan University · ORCID：0000-0001-5389-7550

发表论文 66 篇 · 总被引 203 次 · h-index 5

代表论文

• Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review (2024 · Frontiers in Oncology · 被引 8)
• Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial (2023 · BMC Medicine · 被引 5)
• Evaluation of anti-CD38 monoclonal antibody-based immunotherapy in multiple myeloma with renal insufficiency: a systematic review and meta-analysis (2025 · Therapeutic Advances in Hematology · 被引 3)
• A predictive risk‐scoring model for survival prognosis of multiple myeloma based on gain/amplification of 1q21: Experience in a tertiary hospital in South‐Western China (2024 · Cancer Medicine · 被引 3)
• Maintenance therapy for cytogenetically high-risk multiple myeloma: landscape in the era of novel drugs (2024 · Clinical and Experimental Medicine · 被引 3)
• A comprehensive analysis of bone marrow-derived cytogenetic abnormalities in multiple myeloma patients with extramedullary disease (2025 · Journal of Cancer Research and Clinical Oncology · 被引 2)